Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.64 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27288519 | 1.00 | ESR1 (0.64) | ESR1ESR2CYP3A4MAOAMAOB | |
| SCHEMBL244269 | 1.00 | ESR1 (0.64) | ESR1ESR2CYP3A4MAOAMAOB | |
| SCHEMBL30362800 | 1.00 | ESR1 (0.64) | ESR1ESR2CYP3A4MAOAMAOB | |
| SCHEMBL24103716 | 1.00 | ESR1 (0.64) | ESR1ESR2CYP3A4MAOAMAOB | |
| SCHEMBL2717066 | 0.94 | ESR1 (0.57) | ESR1ESR2CYP3A4MAOAMAOB | |
| SCHEMBL10074006 | 0.94 | ESR1 (0.57) | ESR1ESR2CYP3A4MAOAMAOB | |
| SCHEMBL30362812 | 0.94 | ESR1 (0.57) | ESR1ESR2CYP3A4MAOAMAOB | |
| SCHEMBL243810 | 0.94 | ESR1 (0.57) | ESR1ESR2CYP3A4MAOAMAOB | |
| SCHEMBL21613691 | 0.94 | ESR1 (0.57) | ESR1ESR2CYP3A4MAOAMAOB | |
| SCHEMBL18898251 | 0.94 | ESR1 (0.57) | ESR1ESR2CYP3A4MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233519-A1 | COMBINATION THERAPIES | Aardvark Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| WO-2021252776-A1 | COMBINATION THERAPIES | MEI PHARMA, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233519-A1 | COMBINATION THERAPIES | BCL2, BAK1, BCL2L2 | ESR1 3784/4885ESR2 2187/4885CYP3A4 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.